Tourette Syndrome Market to Grow at a Substantial Growth Rate During the Forecast Period (2019-32) - Estimates DelveInsight | Key Companies - SciSparc (SCI-110), Emalex Biosciences (Ecopipam), Noema Pharma, Asarina, EuMentis, Synendos, Teva Pharmaceutical

As per DelveInsight, the Tourette Syndrome Market is anticipated to grow in the coming years owing to the rise in the number of prevalent cases, the continuous improvement in the research and development activities by the major pharmaceutical giants, and the launch of emerging therapies in the market.

DelveInsight's "Tourette Syndrome Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Tourette Syndrome Market Size and Share in the 7MM (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Tourette Syndrome market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Tourette Syndrome: An Overview
Tourette Syndrome (TS) or Tourette disorder is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Tics are sudden twitches, movements, or sounds that people repeatedly make. They can be of two types-motor and vocal. Of these, motor tics are movements of the body, such as blinking or jerking an arm, whereas vocal tics are sounds that a person makes with his or her voice, such as humming. Motor tics generally precede the development of vocal tics, and simple tics often precede complex tics.

Most people with Tourette Syndrome require no medication for tic suppression because tic symptoms often do not cause impairment; however, effective medications are available for those whose symptoms interfere with functioning.

Tourette Syndrome Market Key Facts
- As per the Tourette Association of America, Tics occur in as many as 1 in 5 school-aged children at some point, but may not persist. Additionally, the organization suggested that the combined estimate of the occurrence of Tourette Syndrome and other Tic Disorders is more than 1 in 100 (1%) school-aged children in the US.
- According to The Recovery Village Drug and Alcohol Rehab, the prevalence of Tourette Syndrome is much higher in boys than in girls. Boys are 3 to 4 times as likely to have Tourette's as girls.

Tourette Syndrome Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Tourette Syndrome market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Tourette Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Tourette Syndrome Market will Grow by 2032:
https://www.delveinsight.com/report-store/tourette-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Tourette Syndrome Epidemiology
The epidemiology section covers detailed insights into the historical and current Tourette Syndrome patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Tourette Syndrome Epidemiology, Segmented by -
- Prevalent Population of Tourette Syndrome in the 7MM (2019-2032)
- Age-specific Prevalent Population of Tourette Syndrome in the 7MM (2019-2032)
- Gender-specific Prevalent Population of Tourette Syndrome in the 7MM (2019-2032)
- Diagnosed and Treatable Cases of Tourette Syndrome in the 7MM (2019-2032)

Get Key Insights Into the Evolving Tourette Syndrome Epidemiology Trends:
https://www.delveinsight.com/report-store/tourette-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Tourette Syndrome Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tourette Syndrome market or expected to be launched during the study period. The analysis covers Tourette Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Tourette Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/report-store/tourette-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Latest Clinical, Commercial, and Regulatory Developments in the Tourette Syndrome Market
- On January 11, 2023, Emalex Biosciences published phase 2b results for Tourette Syndrome candidates in pediatrics. The Phase 2b clinical trial involving more than 150 children and adolescents with Tourette syndrome found ecopipam significantly reduced the total number of tics compared to placebo.
- On August 01, 2022, SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc") announced the addition of another site of excellence, the Yale Child Study Center at Yale University, to its Phase IIb clinical trial for SCI-110 in patients suffering from Tourette Syndrome ("TS").
- In February 2022, Asarina Pharma announced that 'First Patient First Visit' has taken place in its phase IIa clinical study in Tourette syndrome at Bispebjerg University Hospital, Copenhagen.
- In August 2021, Noema Pharma announced the initiation of its first clinical trial, a Phase IIa dose-ranging study of the PDE10A inhibitor NOE-105 in Tourette syndrome. The Allevia trial is a multi-center 12-week prospective study to evaluate the safety and efficacy of once-a-day NOE-105, one of Noema's extensive pipeline of products in-licensed from Roche, at a daily dose range of 5 mg to 15 mg in adult male patients with Tourette syndrome.

Tourette Syndrome Therapeutics Assessment
Currently, there is no cure for Tourette Syndrome. The treatment aims to control tics that interfere with everyday activities and functioning. Often, the majority of people with Tourette Syndrome require no medication for tic suppression because the symptoms do not cause impairment. Moreover, Tourette Syndrome patients experience peak tic severity before the mid-teen years, with improvement in the late teen years and early adulthood.

To improve the Tourette Syndrome Therapeutics' outlook, several major pharma and biotech giants are developing therapies for Tourette syndrome. The pipeline of Tourette Syndrome possesses a few mid-phase potential therapies anticipated to hit the market in the upcoming years. Currently, Emalex Biosciences is leading the therapeutics market with its Tourette syndrome drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Tourette Syndrome Therapeutics Market Include:
- Emalex Biosciences
- Noema Pharma
- Asarina Pharma
- Teva Pharmaceutical
- SciSparc
- EuMentis Therapeutics
- Synendos Therapeutics
And Many Others

Tourette syndrome Drugs Covered in the Report Include:
- Ecopipam: Emalex Biosciences
- SCI-110 (formerly THX-110): SciSparc
And Many More

Learn More About the Emerging Therapies & Key Companies in the Tourette Syndrome Therapeutics Market:
https://www.delveinsight.com/sample-request/tourette-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Tourette Syndrome Competitive Intelligence Analysis
4. Tourette Syndrome Market Overview at a Glance
5. Tourette Syndrome Background and Overview
6. Tourette Syndrome Patient Journey
7. Tourette Syndrome Epidemiology and Patient Population
8. Tourette Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Tourette Syndrome Unmet Needs
10. Key Endpoints of Tourette Syndrome Treatment
11. Tourette Syndrome Marketed Products
12. Tourette Syndrome Emerging Therapies
13. Tourette Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Tourette Syndrome Market Outlook (7 major markets)
16. Tourette Syndrome Access and Reimbursement Overview
17. KOL Views on the Tourette Syndrome Market.
18. Tourette Syndrome Market Drivers
19. Tourette Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/tourette-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Trending Market Research Reports 2032 | DelveInsight

Technical Due Diligence Firms- https://www.delveinsight.com/consulting/due-diligence-services

Vital Sign Monitors Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market

Anastomosis Device Market- https://www.delveinsight.com/report-store/anastomotic-leak-devices-market

Asperger Syndrome Market- https://www.delveinsight.com/report-store/asperger-syndrome-market

B-Cell Maturation Antigen Targeted Therapies Market- https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market

UK Healthcare Report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report

Oncolytic Virus Cancer Therapy Pipeline- https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Shingles Market- https://www.delveinsight.com/report-store/shingles-market

Progressive Supranuclear Palsy Market- https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market

Tay-Sachs Disease Market- https://www.delveinsight.com/report-store/tay-sachs-disease-market

Shigellosis Market- https://www.delveinsight.com/report-store/shigellosis-market

Gene Therapy In CNS Disorder Market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market

Hypertrophic Cardiomyopathy Market- https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market

Varicella Zoster (HHV-3) Infections Market- https://www.delveinsight.com/report-store/varicella-zoster-hhv-3-infections-market

Vasculitis Market- https://www.delveinsight.com/report-store/vasculitis-market

Vascular Imaging Devices Market- https://www.delveinsight.com/report-store/vascular-imaging-market-market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.